Ann Clin Virol | Volume 2, Issue 1 | Mini Review | Open Access

Management of CMV Viremia in Renal Transplant Patients from Perspective of Clinical Practice within United Kingdom

Syed Hasan Ahmad

Department of Nephrology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, UK

^*Correspondance to: Syed Hasan Ahmad 

Fulltext PDF

Abstract

Immunosuppression is an important aspect of management after kidney transplantation for maintenance of graft function. Cytomegalovirus infection in renal transplant patients is reactivation of the latent virus under the influence of immunosuppression. CMV viral load should be regularly monitored and treatment instituted with twice daily dosing if it is above the threshold of 10,000 copies/ml and when a patient is symptomatic. Severe refractory cases can be treated with CMV immune globulin or IVIG. New antiviral treatments like maribavir and brincidofovir are novel drugs that can be used for refractory disease. However, their use is limited, and more studies are currently needed before their widespread use.

Keywords:

Renal transplant; Immunosuppression; Viremia; Ganciclovir

Citation:

Ahmad SH. Management of CMV Viremia in Renal Transplant Patients from Perspective of Clinical Practice within United Kingdom. Ann Clin Virol. 2021;2(1):1004.